References
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30
- SEER Program (National Cancer Institute (U.S.)), National Center for Health Statistics (U.S.), National Cancer Institute (U.S.). Surveillance Program, National Cancer Institute (U.S.). Cancer Statistics Branch, National Cancer Institute (U.S.). Cancer Control Research Program. SEER Stat Fact Sheets: Prostate. NIH publication 2012. Available at: http://seer.cancer.gov/statfacts/html/prost.html [last accessed 30 Aug 2013]
- Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367:203-13
- Martin RM. Commentary: prostate cancer is omnipresent, but should we screen for it? Int J Epidemiol 2007;36:278-81
- Andriole GL, Crawford ED, Grubb RL 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-19
- Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155:762-71
- Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA Guideline. J Urol 2013;190:419-26
- Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005. J Natl Cancer Inst 2009;101:1325-9
- Swindle P, Eastham JA, Ohori M, et al. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 2005;174:903-7
- Ghia AJ, Shrieve DC, Tward JD. Adjuvant radiotherapy use and patterns of care analysis for margin-positive prostate adenocarcinoma with extracapsular extension: postprostatectomy adjuvant radiotherapy: a SEER analysis. Urology 2010;76:1169-74
- Cuzick J, Swanson GP, Fisher G, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 2011;12:245-55
- Cooperberg MR, Simko JP, Cowan JE, et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol 2013;31:1428-34
- Cuzick J, Berney DM, Fisher G, et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer 2012;106:1095-9
- Freedland SJ, Gerber L, Reid J, et al. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int J Radiat Oncol Biol Phys 2013;86:848-53
- Hayes DF, Allen J, Compton C, et al. Breaking a vicious cycle. Sci Transl Med 2013;5:196cm6
- Pothier K, Gustavsen G. Combating complexity: partnerships in personalized medicine. Personalized Medicine 2013;10:387-96
- Malone B. Molecular Diagnostics Reimbursement in Flux. Clinical Laboratory News. Vol 39: American Association for Clinical Chemistry, 2013
- Shore N, Concepcion R, Saltzstein D, et al. Assessment of a cell cycle gene expression assay in biopsies from patients with newly diagnosed prostate adenocarcinoma. Submitted